| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |


From the Abteilung Organisation komplexer Genome,*
Deutsches Krebsforschungszentrum, Heidelberg; Klinik für Mund-,
Kiefer-, Gesichtschirurgie
and
Pathologisches Institut,§
Ruprecht-Karls-Universität, Heidelberg; Institut für
Dermatohistologie und Oralpathologie,¶
Heidelberg; Institut für Neuropathologie,||
Heinrich-Heine-Universität, Düsseldorf; and Klinik und
Poliklinik für zahnärztliche Chirurgie und für Mund-,
Kiefer-, Gesichtschirurgie,
Universität
zu Köln, Köln, Germany
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
In most studies on the genetic alterations in cancer of the upper aerodigestive tract, OSCCs are included in the more heterogeneous group of squamous cell carcinomas (SCCs) of the head and neck (HNSCCs). In HNSCCs, losses of genomic material were identified on 3p, 5q, 7q, 8p, 9p, 11q, 13q, 17p, and 18q by chromosome banding and/or allelotyping.4-8 Cytogenetic gains were found on 1q, 3q, 8q, and 15q.4,5 By comparative genomic hybridization (CGH),9-13 gains in HNSCCs were most frequently detected on 1q, 3q, 5p, 7q, and 8q, whereas losses were most commonly found on 1p, 3p, 5q, 11q, 13q, and 19.14-16 Less is known about genetic changes in OPLs. Molecular genetic analyses revealed loss of heterozygosity (LOH) at 3p, 9p, 17p, and 18q in dysplasias and additionally at 11q, 13q, and 14q in CIS.17-20
Most of the above-mentioned studies were performed on resection specimens obtained at surgery when therapy decisions had already been made. It was the aim of our study to make use of the little material obtained on biopsy of oral epithelial lesions of unknown malignancy that were made for diagnostic reasons before the patients were started on any therapy regimen. Biopsies were histopathologically classified as dysplasia (n = 8), CIS (n = 4), or OSCC (n = 14) and screened for chromosomal imbalances by CGH. To exclusively analyze cells representative of the diagnosis, precise tissue areas were microdissected and their DNA was universally amplified before CGH analysis. As this approach provides comprehensive information on the genomic alterations of an oral epithelial lesion before treatment, it could supplement histopathological findings and assist in identifying prognostic parameters as a basis for therapy decisions.
| Materials and Methods |
|---|
|
|
|---|
Material was obtained from oral biopsies routinely performed for
diagnostic purposes in the Clinic for Oral and Maxillofacial Surgery,
University of Heidelberg, Germany. The biopsy material was fixed in 4%
PBS-buffered formalin for no longer than 4 hours, paraffin-embedded,
and sectioned. The hematoxylin and eosin (H&E)-stained sections were
classified by an oral pathologist (IAB) according to the World Health
Organization classification.21
Lesions consisted of 8
dysplasias (1 mild, 5 moderate, and 2 severe dysplasias), 4 CIS, and 14
carcinomas (3 carcinomas of grade 1, 9 of grade 2, and 2 of grade 3).
The clinical course of the patients whose biopsies were examined was
monitored from January 1996 to December 1997. Of the patients with
OSCC, one had metastases at diagnosis (patient 4) and two developed
metastases during the follow-up period (patients 5 and 14). None of the
patients diagnosed with OPL developed an OSCC during the follow-up
period of 23 months. Consumption of alcohol and tobacco was assessed in
all patients. Patients with a regular alcohol intake of greater than
50 g per day were given the symbol A, and patients who regularly
smoked more than 10 cigarettes per day were given the symbol T in
Figure 1
.
|
The preparation of high molecular weight DNA from peripheral blood leukocytes as control DNA was carried out as described.22 The test DNA was obtained by microdissection of 50100 cells of a defined histopathological entity from an H&E-stained, formalin-fixed, paraffin-embedded biopsy section. For microdissection, a glass needle was produced from a glass capillary using a microforge. Microdissection was then performed using an inverted microscope with the glass needle attached to a de Fonbrune micromanipulator. The microdissected tissue was placed into a tube containing 20 µl 100 mmol/L Tris-HCl buffer (pH 7.5) and digested with 1 µl proteinase K (10 mg/ml) for 3 h at 55°C. The enzyme was then inactivated by incubation at 90°C for 10 minutes.
Degenerate Oligonucleotide Primed-Polymerase Chain Reaction
Degenerate oligonucleotide primed-polymerase chain reaction (DOP-PCR) was used to universally amplify both the test and the control DNA in a thermal cycler. The protocol used was modified from Telenius et al.23 PCR was done in a final volume of 50 µl (4 µl 25 mmol/L MgCl2, 5 µl 10x PCR buffer (500 mmol/L KCl, 100 mmol/L Tris-HCl, pH 8.3) with 2 µl 5 mmol/L deoxynucleotide triphosphate, 5 µl 17 µM primer 6MW (5'-CCG ACT CGA GNN NNN NAT GTG G-3'), 0.5 µl (2.5 U) Taq polymerase, and test or control DNA in 20 µl 100 mmol/L Tris-HCl, pH 7.5). The PCR conditions used were: 10 minutes at 93°C, followed by 10 cycles of 1 minute at 94°C, 1.3 minutes at 30°C, 3-minute transition at 3072°C, and 3-minute extension at 72°C, followed by 35 cycles of 1 minute at 94°C, 1 minute at 62°C, 3 minutes at 72°C with an addition of 1 second/cycle to the extension step, and a final extension of 10 minutes.
CGH
Following standard procedures, metaphase spreads were prepared from stimulated peripheral blood lymphocytes obtained from a healthy male subject (46,XY). CGH was performed with test and control DNA amplified by DOP-PCR as described in detail elsewhere.24 For image acquisition and processing, an epifluorescence microscope (Zeiss Axiophot, Jena, Germany) was used that was equipped with a cooled charge-coupled device camera (Photometrics, Tucson, AZ). Digital images were processed with a program developed by du Manoir et al25 on the basis of the software package TCL-Image (TNO Institute of Applied Physics, Delft, The Netherlands). Mean ratio profiles were determined from the analysis of 10 metaphase spreads. The diagnostic threshold values used to score losses and gains were 0.75 (lower threshold) and 1.25 (upper threshold), respectively, in accordance with previously reported CGH analysis protocols.25 Due to the suppression with Cot1 DNA, the fluorescence intensities were not representative at chromosome regions with tandem repetitive DNA clusters. These areas were excluded from evaluation. Banding assignment of losses and gains was based on the comparison of CGH average ratio profiles and chromosome ideograms.
Microsatellite Analysis
Microsatellite locus D4S426 (4q35) was studied for LOH in the dysplasia and the carcinoma from patient 1. PCR amplification, denaturing polyacrylamide electrophoresis of PCR products, silver staining of the gels, and assessment for allelic loss was performed as described.26
Control Experiments
To validate our approach combining the microdissection of H&E-stained biopsy sections followed by DOP-PCR and CGH, various control experiments were performed.
Negative control experiments were carried out to specifically validate the DOP-PCR protocol used by hybridizing differently labeled, DOP-PCR-amplified control DNAs to reference chromosomes. As a further control experiment, DNA obtained from connective tissue microdissected from biopsy sections and amplified by DOP-PCR was hybridized together with differently labeled DOP-PCR-amplified control DNA to reference chromosomes. In these control experiments, no imbalances were detected on any chromosome except on 19, X and Y once each (four experiments). As artifactual results had been occasionally observed in our and other laboratories on chromosome 19 and chromosomal bands 1p34p36,27-29 these regions as well as the sex chromosomes were excluded from the analysis.
Positive control experiments were performed with DNA extracted conventionally from OSCC tissue. Results from CGH experiments performed with 1) OSCC DNA versus control DNA and 2) the same OSCC DNA versus control DNA, but both amplified by DOP-PCR, were compared. The chromosomal imbalances identified by CGH in the OSCC DNAs that had not been subjected to DOP-PCR were again detected in the experiments with the same OSCC DNAs that had been universally amplified by DOP-PCR. To validate CGH results by an independent method, microsatellite analysis was performed at D4S426 on DOP-PCR-amplified DNA from a dysplasia and a carcinoma of patient 1. LOH at this microsatellite marker was identified in both the dysplasia and the carcinoma of this patient. This result was concordant with the CGH findings that loss on chromosome arm 4q was present in both lesions.
Statistics
Given are means ± SEM. After assessment for normal distribution by the Shapiro-Wilks test, comparisons between groups were performed by Mann-Whitney U test. P < 0.05 was considered statistically significant.
| Results |
|---|
|
|
|---|
Oral Dysplasias and CIS (Premalignant Lesions)
An average of 2.9 ± 1.3 genomic alterations was detected in
the 8 dysplasias. In the 4 CIS studied, the average number of
chromosomal imbalances was slightly higher (3.8 ± 2.8). When
combining all 12 premalignant lesions, an average of 3.2 ± 1.2
genomic changes per case was found (Figure 2)
.
|
|
|
In the 14 carcinomas examined, the average number of chromosomal
imbalances was significantly higher (11.9 ± 1.9) than in the OPLs
(P = 0.003) (Figure 2)
.
The following chromosomal alterations were identified in more than
three carcinomas: gains on 20q (8 of 14, 57%); 8q, 11q, and 22q (7 of
14, 50% each); 3q, 15q, and 17p (6 of 14, 43% each); 14q, 17q, and
20p (5 of 14, 36% each); 1q, 5p, 7q, and 16p (4 of 14, 29% each) and
losses on 3p and 4q (9 of 14, 64% each); 5q (7 of 14, 50%); 13q (6 of
14, 43%); 2q and 9p (5 of 14, 36% each); and 4p, 6q, and 8p (4 of 14,
29% each) (Figures 3 and 4)
.
Of the 14 OSCCs investigated, 3 were metastasizing. The mean number of genomic alterations was higher in these 3 cases than in the 11 nonmetastasizing tumors (15 ± 2.5 versus 11.1 ± 2.4). The DNA copy number changes common to all 3 metastasizing OSCCs were gains on 3q, 15q, 17p, and 20q, as well as losses on 3p and 9p.
Comparison of Lesions of Different Histopathology within One Biopsy
In eight biopsies with the histopathological diagnosis of carcinoma, premalignant lesions were also found in other areas of the biopsy material. In these cases, cells from dysplasia, CIS, and carcinoma from the same patient were microdissected separately and analyzed.
In 4 biopsies (patients no. 2, 4, 5, and 7), no or only one genomic
alteration was found in the premalignant lesions and 0, 2, 12, and 13
abnormalities in the respective carcinomas. Figure 5A
shows CGH results obtained for patient
5 comparing average ratio profiles detected in the dysplasia and the
carcinoma of this patient. In the other 4 biopsies (patients no. 1, 3,
8, and 10), 5 or more changes were identified in the premalignant
lesions and 11 or more anomalies in the respective carcinomas (5, 8, 8,
and 12 (changes in OPLs) versus 18, 11, 11, and 15 (changes
in OSCCs)). Chromosomal imbalances found in the dysplasia and the
carcinoma of patient 1 are shown in Figure 5B
. Of the 36 CGH
abnormalities detected in premalignant lesions, 30 (83%)
were again found in the respective carcinomas (Figure 6)
.
|
|
| Discussion |
|---|
|
|
|---|
In this study, we used CGH to identify chromosomal imbalances in 26 oral lesions from 16 patients diagnosed as dysplasia, CIS, or invasive SCC. The stringent diagnostic thresholds that we use for CGH analysis25 require a high percentage of cells to be tested within the tissue used for DNA extraction and amplification. As CIS and particularly dysplasias represent alterations of a few defined cells within the oral epithelium, the isolation of a precise tissue area is a prerequisite for CGH analysis. Similarly, SCCs may contain a significant component of nonneoplastic cells, such as inflammatory cells, as well as connective tissue. In our study, we therefore performed microscopic dissection of areas of 50 to 100 histopathologically defined cells with the aid of a glass needle and a micromanipulator. To achieve a precise cellular identification, H&E-stained tissue sections were used for microdissection. This approach allowed a more reliable microdissection of defined cells as compared with using an unstained section consecutive to a H&E-stained section.
The DNA from the microdissected tissue was then universally amplified using a modified DOP-PCR protocol23 (see Materials and Methods). Negative and positive control CGH experiments confirmed the validity of using this DOP-PCR protocol for the generation of genomic DNA as probes for CGH (see Materials and Methods). The reliability of this approach was further corroborated by the detection of LOH on 4q in a dysplastic lesion and an OSCC from the same patient that had both been found to have losses on 4q by CGH. Thus, tissue microdissection followed by universal DNA amplification and CGH represent a strategy that allows the detection of chromosomal imbalances even in small precursor lesions representing an early stage of the tumor progression pathway. Previously, a combination of these techniques was performed on a few tumors of different types. These included one human testicular tumor versus adjacent normal testis tissue,30 three primary human cutaneous malignant melanomas in different growth phases,31 and seven ductal CIS that represent precursor lesions of invasive ductal breast cancer.32
Genomic Alterations in OPLs and OSCCs
In 8 of the 12 OPLs analyzed here, no or only one genomic alteration was detected, whereas 5 or more genetic changes were found in the other 4 lesions. The most frequent losses identified included those on 3p, 9p, and 13q, which had previously been reported in OPLs by LOH analyses.7,17-19,33 Additionally, losses on 4q, 5q, and 8p were detected in our study. The gains identified by CGH in more than one case were located on 8q and 16p.
One of the most frequent alterations detected in OSCCs was loss on 3p. On this chromosome arm, three distinct regions of deletion were previously identified, of which the most proximal (3p13p21.1) and the most distal (3p25) were found to occur in oral dysplastic lesions at the same frequency as in OSCCs.19 In our study, a commonly deleted region in OPLs and OSCCs encompassed 3p25p26. This region contains the VHL (von Hippel-Lindau) tumor suppressor gene.34 However, in 26 upper aerodigestive tract SCCs that were known to have lost one allele at 3p, neither mutations nor hypermethylation was found in the remaining allele of the VHL gene,35 making VHL an unlikely "target" for the distal 3p deletion. Losses detected on 9p in OPLs and OSCCs in this report included the locus of tumor suppressor gene CDKN2A (p16/MTS1/INK4a). Loss of p16 expression was found by immunohistochemistry in 38% of oral dysplastic lesions36 and in 50% of HNSCC cell lines.37 In our study, loss on 13q was detected in 25% of OPLs, a percentage similar to that identified by LOH studies.17 The smallest commonly deleted region found comprised 13q22q31.
Losses on 4q, 8p, and 5q, which were identified in OPLs and in higher percentages of OSCCs in our study, had previously only been identified in HNSCCs: LOH on 4q was seen in the majority of HNSCCs with a common region of deletion at 4q25 containing the EGF locus;38 on 8p, multiple distinct regions of allelic loss (8p21, 8p22p23, and 8p23) were detected in SCC of the supraglottic larynx;39 LOH on 5q was shown to involve the APC gene in OSCC,40 which is located within the commonly deleted region identified in OPLs (5q11.2q23) and OSCCs (5q21q23) here. According to our results, particularly the loss on 5q that was found in one-third of OPLs may in fact be a previously unidentified genetic alteration that occurs in the progression pathway before the invasive carcinoma stage.
In our study, 3 of 12 OPLs and 7 of 14 OSCCs revealed gain on 8q with a smallest region of common gain including the MYC proto-oncogene locus at 8q24.41 In oral SCCs, MYC was previously shown to be amplified42,43 and overexpressed,44 making this gene the likely "target" for the gain on 8q in OPLs and OSCCs described here.
Clonality of Different Lesions within the Oral Mucosa
The observation that histopathological abnormalities are common in the vicinity of invasive carcinomas from the oral cavity was first made by Slaughter et al. and termed field cancerization.2 In eight patients with OSCC studied here, areas of dysplasia and/or CIS were identified within the same biopsy and examined additionally. Six OSCCs displayed the same alterations as the respective OPLs and additional DNA copy number changes. In only three cases, a small fraction of chromosomal imbalances identified in the OPLs were not found in the respective OSCCs. These data support the hypothesis that field cancerization is caused by the migration and expansion of clonally related cells in a high proportion of cases. Additional evidence that multiple lesions within the mucosa of the head and neck arise from a single progenitor clone was provided by studies of allelic loss and X chromosome inactivation in lesions with different histopathological appearance and multiple primary tumors from the same patients.17,45
Genomic Alterations as Prognostic Parameters
The chromosomal imbalances identified in biopsy material diagnosed as OSCC in this study are similar to those detected in a CGH study on 30 primary tumor specimens of HNSCC obtained at surgical resection.16 This is particularly interesting, as it demonstrates that CGH can be reliably performed on biopsy material, which is obtained from the patient when the oral lesion is first diagnosed, before a therapeutic decision has been made. Together with the histopathological classification, the genomic alterations of an oral lesion determined at such an early time point could eventually be used as prognostic indicators that could assist in the choice of the best therapeutic strategy.
As a first step in this direction, it is of interest to determine the most likely sequence in which genomic alterations occur during the progression from premalignant lesions to invasive carcinomas. Such genetic models have been proposed for the development from normal mucosa to hyperplasia (9p loss), dysplasia (3p, 17p loss), CIS (11q, 13q and 14q loss), and invasive HNSCC (6p, 8, and 4q loss) based on microsatellite analyses for allelic loss at 10 chromosomal loci.17 Other models are based on compilations of the literature.20,46 A CGH study postulated that distinct patterns of gains and losses were associated with HNSCC of different histological grades (grade 1, losses on 3p, 9p, and gain on 3q; grade 3, additional losses on 4q, 8p, 11q, 13q, 18q, and 21q, and gains on 1pter, 11q13, 19, and 22q).16 In our study, a genome-wide screening for chromosomal imbalances was possible not only in pure tumor cell populations from OSCCs but also in oral dysplasias and CIS. Compared with the above-mentioned reports, the additional alterations identified here in more than one-fourth of OPLs were loss on 5q and gain on 8q and in more than one-third of OSCCs gains on 14q and 15q and losses on 2q.
To be able to base therapy decisions on the genetic abnormalities identified, it is necessary to correlate the respective chromosomal changes with the clinical course of the patient, ie, with the development of invasive carcinoma from OPLs or of metastases from SCCs, or with patient survival. Mao et al33 found that detection of allelic loss at 9p21 and 3p14 in OPLs may aid in assessing the risk for progression to carcinoma. They reported that more than one-third of patients with LOH at one of these loci developed OSCCs, whereas only 6% of patients without allelic loss did so. In our study, the mean number of genomic alterations was higher in the 3 metastasizing carcinomas than in the 11 nonmetastasizing tumors. This is in line with the findings by Soder et al47 that diploidy was significantly more common in nonmetastasizing carcinomas and that aneuploidy predominated in the group of metastasizing HNSCCs. The chromosomal imbalances attributed to metastasizing versus nonmetastasizing HNSCCs by Bockmühl et al48 differ from our results for metastasizing OSCCs except for overrepresentation of 20q, which was frequently found in both studies. In some reports, genetic changes were correlated with patient survival. In HNSCCs, the fractional allele loss calculated for 52 tumors,49 LOH at 3p,50 and rearrangements at 11q1351 were associated with a reduction in survival time.
By our combined approach, comprehensive information on the chromosomal imbalances in small biopsies of oral epithelial lesions could be obtained. Such data may assist in identifying prognostic parameters that could in future be used as a basis for patient counseling and therapeutic decisions.
| Acknowledgements |
|---|
| Footnotes |
|---|
Supported by the Deutsche Krebshilfe (grants 10-1124-Li1 and 10-0976-Re1).
Accepted for publication April 7, 1998.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
H. S. Patmore, L. Cawkwell, N. D. Stafford, and J. Greenman Unraveling the Chromosomal Aberrations of Head and Neck Squamous Cell Carcinoma: A Review Ann. Surg. Oncol., October 1, 2005; 12(10): 831 - 842. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. A. Bergamo, L. C. da Silva Veiga, P. P. dos Reis, I. N. Nishimoto, J. Magrin, L. P. Kowalski, J. A. Squire, and S. R. Rogatto Classic and Molecular Cytogenetic Analyses Reveal Chromosomal Gains and Losses Correlated with Survival in Head and Neck Cancer Patients Clin. Cancer Res., January 15, 2005; 11(2): 621 - 631. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Richter, P. Slezak, A. Walch, M. Werner, H. Braselmann, E. Jaramillo, A. Ost, I. Hirata, K. Takahama, and H. Zitzelsberger Distinct Chromosomal Imbalances in Nonpolypoid and Polypoid Colorectal Adenomas Indicate Different Genetic Pathways in the Development of Colorectal Neoplasms Am. J. Pathol., July 1, 2003; 163(1): 287 - 294. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Estilo, P. O-charoenrat, I. Ngai, S. G. Patel, P. G. Reddy, S. Dao, A. R. Shaha, D. H. Kraus, J. O. Boyle, R. J. Wong, et al. The Role of Novel Oncogenes Squamous Cell Carcinoma-related Oncogene and Phosphatidylinositol 3-Kinase p110{alpha} in Squamous Cell Carcinoma of the Oral Tongue Clin. Cancer Res., June 1, 2003; 9(6): 2300 - 2306. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Freier, S. Joos, C. Flechtenmacher, F. Devens, A. Benner, F. X. Bosch, P. Lichter, and C. Hofele Tissue Microarray Analysis Reveals Site-specific Prevalence of Oncogene Amplifications in Head and Neck Squamous Cell Carcinoma Cancer Res., March 15, 2003; 63(6): 1179 - 1182. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. H. Stoecklein, A. Erbersdobler, O. Schmidt-Kittler, J. Diebold, J. A. Schardt, J. R. Izbicki, and C. A. Klein SCOMP Is Superior to Degenerated Oligonucleotide Primed-Polymerase Chain Reaction for Global Amplification of Minute Amounts of DNA from Microdissected Archival Tissue Samples Am. J. Pathol., July 1, 2002; 161(1): 43 - 51. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Joos, C. K. Menz, G. Wrobel, R. Siebert, S. Gesk, S. Ohl, G. Mechtersheimer, L. Trumper, P. Moller, P. Lichter, et al. Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2 Blood, February 15, 2002; 99(4): 1381 - 1387. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Redon, D. Muller, K. Caulee, K. Wanherdrick, J. Abecassis, and S. du Manoir A Simple Specific Pattern of Chromosomal Aberrations at Early Stages of Head and Neck Squamous Cell Carcinomas: PIK3CA but not p63 Gene as a Likely Target of 3q26-qter Gains Cancer Res., May 1, 2001; 61(10): 4122 - 4129. [Abstract] [Full Text] |
||||
![]() |
J. Sudbo, W. Kildal, B. Risberg, H. S. Koppang, H. E. Danielsen, and A. Reith DNA Content as a Prognostic Marker in Patients with Oral Leukoplakia N. Engl. J. Med., April 26, 2001; 344(17): 1270 - 1278. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Fend and M. Raffeld Laser capture microdissection in pathology J. Clin. Pathol., September 1, 2000; 53(9): 666 - 672. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Bockmuhl, K. Schluns, I. Kuchler, S. Petersen, and I. Petersen Genetic Imbalances with Impact on Survival in Head and Neck Cancer Patients Am. J. Pathol., August 1, 2000; 157(2): 369 - 375. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Morifuji, S.’i. Taniguchi, H. Sakai, Y. Nakabeppu, and M. Ohishi Differential Expression of Cytokeratin after Orthotopic Implantation of Newly Established Human Tongue Cancer Cell Lines of Defined Metastatic Ability Am. J. Pathol., April 1, 2000; 156(4): 1317 - 1326. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Joos, M. Küpper, S. Ohl, F. von Bonin, G. Mechtersheimer, M. Bentz, P. Marynen, P. Möller, M. Pfreundschuh, L. Trümper, et al. Genomic Imbalances Including Amplification of the Tyrosine Kinase Gene JAK2 in CD30+ Hodgkin Cells Cancer Res., February 1, 2000; 60(3): 549 - 552. [Abstract] [Full Text] |
||||
![]() |
A. K. Walch, H. F. Zitzelsberger, J. Bruch, G. Keller, D. Angermeier, M. M. Aubele, J. Mueller, H. Stein, H. Braselmann, J. R. Siewert, et al. Chromosomal Imbalances in Barrett’s Adenocarcinoma and the Metaplasia-Dysplasia-Carcinoma Sequence Am. J. Pathol., February 1, 2000; 156(2): 555 - 566. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |